<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st May 2013//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_130501.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">24015326</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>9</Month>
            <Day>9</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1948-5875</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>4</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Aug</Month>
                        <Day>8</Day>
                    </PubDate>
                </JournalIssue>
                <Title>ACS medicinal chemistry letters</Title>
                <ISOAbbreviation>ACS Med Chem Lett</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses.</ArticleTitle>
            <Pagination>
                <MedlinePgn>747-751</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">There are currently six nucleoside reverse transcriptase inhibitors (NRTI) that are FDA approved for human clinical use and these remain the backbone of current HIV therapy. In order for these NRTIs to be effective they need to be phosphorylated consecutively by cellular kinases to their triphosphate forms. Herein, we report the synthesis of C-6 modified (-)-β-D-(2R,4R)-1,3-dioxolane adenosine nucleosides and their nucleotides including our novel phosphoramidate prodrug technology. We have introduced a side chain moiety on the phenol portion of the phosphoramidate to reduce the toxicity potential. The synthesized phosphoramidates displayed up to a 3,600-fold greater potency versus HIV-1 when compared to their corresponding parent nucleoside and were up to 300-fold more potent versus HBV. No cytotoxicity was observed up to 100 μM in the various cell systems tested, except for compound 17 and 18 which displayed a CC50 of 7.3 and 12 μM respectively in Huh-7 cells. The improved and significant dual antiviral activity of these novel phosphoramidate nucleosides was partially explained by the increased intracellular formation of the adenosine dioxolane triphosphate.</AbstractText>
            </Abstract>
            <Affiliation>Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Veterans Affairs Medical Center, Decatur, Georgia 30033, USA.</Affiliation>
            <AuthorList>
                <Author>
                    <LastName>Bondada</LastName>
                    <ForeName>Lavanya</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Detorio</LastName>
                    <ForeName>Mervi</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Bassit</LastName>
                    <ForeName>Leda</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Tao</LastName>
                    <ForeName>Sijia</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Montero</LastName>
                    <ForeName>Catherine M</ForeName>
                    <Initials>CM</Initials>
                </Author>
                <Author>
                    <LastName>Singletary</LastName>
                    <ForeName>Tyana M</ForeName>
                    <Initials>TM</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Hongwang</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Longhu</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Jong-Hyun</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author>
                    <LastName>Coats</LastName>
                    <ForeName>Steven J</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author>
                    <LastName>Schinazi</LastName>
                    <ForeName>Raymond F</ForeName>
                    <Initials>RF</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <GrantList>
                <Grant>
                    <GrantID>P30 AI050409</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R37 AI025899</GrantID>
                    <Acronym>AI</Acronym>
                    <Agency>NIAID NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>ACS Med Chem Lett</MedlineTA>
            <NlmUniqueID>101521073</NlmUniqueID>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Dioxolane adenosine nucleoside</Keyword>
            <Keyword MajorTopicYN="N">HBV</Keyword>
            <Keyword MajorTopicYN="N">HIV</Keyword>
            <Keyword MajorTopicYN="N">ProTide</Keyword>
            <Keyword MajorTopicYN="N">nucleoside reverse transcriptase inhibitor</Keyword>
            <Keyword MajorTopicYN="N">phosphoramidate prodrug</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ml4001497</ArticleId>
            <ArticleId IdType="pubmed">24015326</ArticleId>
            <ArticleId IdType="pmc">PMC3763849</ArticleId>
            <ArticleId IdType="mid">NIHMS501710</ArticleId>
        </ArticleIdList>
        <?nihms?>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>